Study Summary:
A randomized, double-blind, placebo controlled, multicenter, phase II study to evaluate the impact of an investigational study drug on brain amyloid and related biomarkers in patients with mild to moderate Alzheimer's Disease.
Qualified Participants Must:
• Be 50-85 years of age
•
Have a diagnosis of Alzheimer's disease
•
Have a reliable Caregiver to report on subjects daily living activities and behaviors
Qualified Participants May Receive:
Compensation for time and travel and all study related examinations and assessments at no cost.